BioCentury | Jul 30, 2015
Distillery Therapeutics

Therapeutics: Calcium channel; serotonin (5-HT) transporter (SLC6A4; SERT); estrogen receptor; androgen receptor

...diabetes. Orion Corp. , Eisai Co. Ltd. and Kyowa Hakko Kirin Co. Ltd. market Fareston toremifene citrate...
BioCentury | Jul 25, 2013
Distillery Therapeutics

Indication: Infectious disease

...and nonhuman primate infection models. Orion Corp. and Kyowa Hakko Kirin Co. Ltd. market Fareston toremifene citrate...
BioCentury | Oct 8, 2012
Company News

GTx, Orion, Kyowa Hakko Kirin sales and marketing update

...conjunction with the deal termination, GTx sold its U.S. rights to breast cancer drug Fareston toremifene citrate...
...license to market Fareston in the U.S. Torrey Partners acted as financial advisor to GTx. Fareston...
...the U.S. to treat metastatic breast cancer in postmenopausal women. GTx reported $3.5 million in Fareston...
BioCentury | Jul 25, 2011
Company News

Orion, Eisai sales and marketing update

...rights to Orion's breast cancer drug Fareston toremifene citrate and Parkinson's disease (PD) drug Eldepryl selegiline. Fareston...
...June. Terms were not disclosed. Orion reported 2010 sales of €11.7 million ($15.6 million) for Fareston...
BioCentury | Jun 24, 2011
Financial News

GTx raises $47.5 million

...in patients with non-small cell lung cancer (NSCLC). GTx also markets breast cancer drug Fareston toremifene citrate...
BioCentury | Apr 18, 2011
Clinical News

Fareston toremifene citrate regulatory update

...FDA updated the label for breast cancer drug Fareston toremifene citrate to include a boxed warning about...
...to which it has U.S. rights only, from Orion. GTx markets toremifene 60 mg as Fareston...
...GTx Inc. (NASDAQ:GTXI), Memphis, Tenn. Orion Corp. (HSE:ORNAV; HSE:ORNBV), Espoo, Finland Product: Fareston toremifene citrate (formerly Acapodene...
BioCentury | Mar 7, 2011
Company News

GTx, Ipsen deal

...rights only, from Orion Corp. (HSE:ORNAV; HSE:ORNBV, Espoo, Finland). GTx markets toremifene 60 mg as Fareston...
BioCentury | Mar 3, 2011
Company News

GTx falls after toremifene deal terminated

...has U.S. rights only, from Orion Corp. (HSE:ORNAV; HSE:ORNBV). GTx markets toremifene 60 mg as Fareston...
BioCentury | Nov 1, 2010
Finance

Regulatory Milestones

...$40 million through the sale of 14.3 million shares at $2.80 in a follow-on. GTx's toremifene citrate...
...fractures in men with prostate cancer receiving androgen deprivation therapy. GTx also markets toremifene as Fareston...
BioCentury | Oct 28, 2010
Financial News

GTx raises $40 million

...when its stock price was $3.19. GTx fell $0.33 (10%) to $2.86 on Wednesday. GTx's toremifene citrate...
...fractures in men with prostate cancer receiving androgen deprivation therapy. GTx also markets toremifene as Fareston...
Items per page:
1 - 10 of 105